Prevalence of non-alcoholic fatty liver disease and its relation to hypoadiponectinaemia in the middle-aged and elderly Chinese population

Archives of Medical Science

Volumn 7, Issue 4, 2011, Pages 665-672

  Yang, Zhen ^a   Wang, Xuanchun ^a   Wen, Jie ^a   Ye, Zi ^a   Li, Qin ^a   He, Min ^a   Lu, Bin ^a   Ling, Charlotte ^b   Wu, Songhua ^c   Hu, Renming ^a  

^a FUDAN UNIVERSITY   (China)

^b LUND UNIVERSITY DIABETES CENTRE   (Sweden)

^c SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Hypoadiponectinaemia; Non alcoholic fatty liver disease; Prevalence; Risk factor

Indexed keywords

ADIPONECTIN;

ABNORMALLY LOW SUBSTRATE CONCENTRATION IN BLOOD; ADULT; AGED; ARTICLE; CHINESE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; ECHOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HIGH RISK POPULATION; HUMAN; HYPOADIPONECTINEMIA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NONALCOHOLIC FATTY LIVER; POPULATION BASED CASE CONTROL STUDY; PREVALENCE; PROTEIN BLOOD LEVEL; SEX DIFFERENCE;

EID: 80052558297     PISSN: 17341922     EISSN: None     Source Type: Journal    
DOI: 10.5114/aoms.2011.24137     Document Type: Article

References (36)

1. Wu Z, Yao C, Zhao D, et al. Sino-MONICA project: A collaborative study on trends and determinants in cardiovascular diseases in China. Part I: Morbidity and mortality monitoring. Circulation 2001; 103: 462-8. (Pubitemid 32105989)
2. Yao C, Wu Z, Wu Y. The changing pattern of cardiovascular diseases in China. World Health Stat Q 1993; 46: 113-8.
3. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346: 1221-31.
4. Fehér J, Németh E, Lengyel G. Non-alcoholic steatohepatitis (NASH). Arch Med Sci 2005; 1: 37-47.
5. Lazo M, Clark JM. The epidemiology of nonalcoholic fatty liver disease: A global perspective. Semin Liver Dis 2008; 28: 339-50.
6. Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: An autopsy study with analysis of risk factors. Hepatology 1990; 12: 1106-10.
7. Shibata M, Kihara Y, Taguchi M, et al. Nonalcoholic fatty liver disease is a risk factor for type 2 diabetes in middle-aged Japanese men. Diabetes Care 2007; 30: 2940-4. (Pubitemid 350083148)
8. Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003; 37: 917-23. (Pubitemid 36397405)
9. Schindhelm RK, Diamant M, Heine RJ. Nonalcoholic fatty liver disease and cardiovascular disease risk. Curr Diab Rep 2007; 7: 181-7. (Pubitemid 46951915)
10. Yang Z, Zhang Z, Wen J, et al. Elevated serum chemokine CXC ligand 5 levels are associated with hypercholesterolemia but not a worsening of insulin resistance in Chinese people. J Clin Endocrinol Metab 2010; 95: 3926-32.
11. Piestrzeniewicz K, Łuczak K, Maciejewski M, et al. Impact of obesity and adipokines on cardiac structure and function in men with first myocardial infarction. Arch Med Sci 2008; 4: 152-60.
12. Bajaj M, Suraamornkul S, Piper P, et al. Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients. J Clin Endocrinol Metab 2004; 89: 200-6. (Pubitemid 38183882)
13. López-Bermejo A, Botas P, Funahashi T, et al. Adiponectin, hepatocellular dysfunction and insulin sensitivity. Clin Endocrinol (Oxf) 2004; 60: 256-63. (Pubitemid 38200909)
14. Yokoyama H, Hirose H, Ohgo H, et al. Inverse association between serum adiponectin level and transaminase activities in Japanese male workers. J Hepatol 2004; 41: 19-24. (Pubitemid 39005147)
15. Tilg H, Hotamisligil GS. Nonalcoholic fatty liver disease: Cytokine-adipokine interplay and regulation of insulin resistance. Gastroenterology 2006; 131: 934-45. (Pubitemid 44307061)
16. Kamada Y, Tamura S, Kiso S, et al. Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin. Gastroenterology 2003; 125: 1796-807. (Pubitemid 37500444)
17. Xu A, Wang Y, Keshaw H, et al. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 2003; 112: 91-100. (Pubitemid 38056380)
18. Tomita K, Oike Y, Teratani T, et al. Hepatic AdipoR2 signaling plays a protective role against progression of nonalcoholic steatohepatitis in mice. Hepatology 2008; 48: 458-73.
19. Kaser S, Moschen A, Cayon A, et al. Adiponectin and its receptors in non-alcoholic steatohepatitis. Gut 2005; 54: 117-21. (Pubitemid 40007229)
20. Fan JG, Zhu J, Li XJ, et al. Prevalence of and risk factors for fatty liver in a general population of Shanghai, China. J Hepatol 2005; 43: 508-14. (Pubitemid 41111434)
21. Zhou YJ, Li YY, Nie YQ, et al. Prevalence of fatty liver disease and its risk factors in the population of South China. World J Gastroenterol 2007; 3: 6419-24.
22. Targher G, Bertolini L, Rodella S, et al. Associations between plasma adiponectin concentrations and liver histology in patients with nonalcoholic fatty liver disease. Clin Endocrinol (Oxf) 2006; 64: 679-83. (Pubitemid 43775007)
23. Pagano C, Soardo G, Esposito W, et al. Plasma adiponectin is decreased in nonalcoholic fatty liver disease. Eur J Endocrinol 2005; 152: 113-8. (Pubitemid 40185459)
24. Yoneda M, Iwasaki T, Fujita K, et al. Hypoadiponectinemia plays a crucial role in the development of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus independent of visceral adipose tissue. Alcohol Clin Exp Res 2007; 31: S15-21.
25. Yoon D, Lee SH, Park HS, et al. Hypoadiponectinemia and insulin resistance are associated with nonalcoholic fatty liver disease. J Korean Med Sci 2005; 20: 421-6. (Pubitemid 40908921)
26. Saverymuttu SH, Joseph AE, Maxwell JD. Ultrasound scanning in the detection of hepatic fibrosis and steatosis. Br Med J (Clin Res Ed) 1986; 292: 13-5. (Pubitemid 16175875)
27. Joseph AE, Saverymuttu SH, al-Sam S, et al. Comparison of liver histology with ultrasonography in assessing diffuse parenchymal liver disease. Clin Radiol 1991; 43: 26-31.
28. Chavez-Tapia NC, Tellez-Avila FI, Valdes-Escarcega M, et al. Differential risk factor patterns for a positive treadmill test among subjects with and without ultrasound-based fatty liver. Arch Med Sci 2009; 5: 207-14.
29. Fishbein M, Castro F, Cheruku S, et al. Hepatic MRI for fat quantitation: Its relationship to fat morphology, diagnosis, and ultrasound. J Clin Gastroenterol 2005; 39: 619-25. (Pubitemid 41061269)
30. Masaki T, Chiba S, Tatsukawa H, et al. Adiponectin protects LPS-induced liver injury through modulation of TNF-alpha in KK-Ay obese mice. Hepatology 2004; 40: 177-8.
31. Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999; 257: 79-83. (Pubitemid 29299050)
32. Weyer C, Funahashi T, Tanaka S, et al. Hypoadiponectinemia in obesity and type 2 diabetes: Close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001; 86: 1930-5. (Pubitemid 32472900)
33. Sutinen J, Korsheninnikova E, Funahashi T, et al. Circulating concentration of adiponectin and its expression in subcutaneous adipose tissue in patients with highly active antiretroviral therapy-associated lipodystrophy. J Clin Endocrinol Metab 2003; 88: 1907-10. (Pubitemid 36623422)
34. Westerbacka J, Cornér A, Tiikkainen M, et al. Women and men have similar amounts of liver and intra-abdominal fat, despite more subcutaneous fat in women: Implications for sex differences in markers of cardiovascular risk. Diabetologia 2004; 47: 1360-9. (Pubitemid 39232420)
35. Musso G, Gambino R, Durazzo M, et al. Adipokines in NASH: Postprandial lipid metabolism as a link between adiponectin and liver disease. Hepatology 2005; 42: 1175-83. (Pubitemid 43112685)
36. Musso G, Gambino R, Biroli G, et al. Hypoadiponectinemia predicts the severity of hepatic fibrosis and pancreatic beta-cell dysfunction in nondiabetic nonobese patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2005; 100: 2438-46.